Publication Name	World Journal of Gastroenterology
Manuscript ID	114200
Country	China

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Perioperative serum carcinoembryonic antigen: Powerful marker for prognostic prediction and adjuvant chemotherapy decision-making in patients with stage II and III colorectal cancer
Manuscript Source	Unsolicited Manuscript
All Author List	Fen-Qi Du, Jia-Lu Liu, Liu-Dan Mai, Xin-Hao Han, Wen-Jie Song, Da Yang, Qiu-Ju Zhang, Rui Zhang, Yan-Long Liu and Jin-Xue Tong
Funding Agency and Grant Number	Funding Agency Grant Number Heilongjiang Provincial Natural Science Foundation of China PL2024H173 Nn10 Project of Harbin Medical University Cancer Hospital no.04000079
Corresponding Author	Jin-Xue Tong, Professor, Department of Colorectal Surgery, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin 150081, Heilongjiang Province, China. 601705@hrbmu.edu.cn
Key Words	Colorectal cancer; Perioperative carcinoembryonic antigen; Prognostic marker; Recurrence; Metastasis; Adjuvant chemotherapy
Core Tip	Perioperative carcinoembryonic antigen (CEA) is an important prognostic predictor and stratification marker, and it is reasonable to apply perioperative CEA to guide postoperative follow-up of stage II and III colorectal cancer (CRC) patients. The nomogram model based on perioperative CEA can well predict the 3-year, 5-year, and 7-year overall survival and disease-free survival of stage II and III CRC patients. Perioperative CEA can be used to assess recurrence or metastasis features of stage II and III CRC patients. Perioperative CEA, especially postoperative CEA, has the potential to guide adjuvant chemotherapy in stage II and III CRC patients, which is worthy of further study.
Citation	Du FQ, Liu JL, Mai LD, Han XH, Song WJ, Yang D, Zhang QJ, Zhang R, Liu YL, Tong JX. Perioperative serum carcinoembryonic antigen: Powerful marker for prognostic prediction and adjuvant chemotherapy decision-making in patients with stage II and III colorectal cancer. World J Gastroenterol 2026; In press

Received	2025-09-22 03:13
Peer-Review Started	2025-09-22 03:13
First Decision by Editorial Office Director	2025-11-04 09:47
Return for Revision	2025-11-04 09:47
Revised	2025-11-26 09:05
Publication Fee Transferred	2025-11-30 13:26
Second Decision by Editor	2026-01-12 02:37
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-01-12 10:53
Articles in Press	2026-01-12 10:53
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com